scholarly journals Oxycodone/naloxone prolonged‐release tablets in patients with moderate‐to‐severe, chronic cancer pain: Challenges in the context of hepatic impairment

2021 ◽  
Author(s):  
Brian H Le ◽  
Ghauri Aggarwal ◽  
Carol Douglas ◽  
Michael Green ◽  
Amanda Nicoll ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Hepatic Impairment ◽  
Prolonged Release ◽  
Chronic Cancer Pain

High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain

2017 ◽  
Vol 25 (10) ◽  
pp. 3051-3058 ◽  
Author(s):  
Francesco Amato ◽  
Silvia Ceniti ◽  
Sergio Mameli ◽  
Giovanni M. Pisanu ◽  
Renato Vellucci ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Fixed Combination ◽  
Prolonged Release ◽  
Chronic Cancer Pain

scholarly journals Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain

2014 ◽  
Vol 23 (3) ◽  
pp. 823-830 ◽  
Author(s):  
Sam H. Ahmedzai ◽  
Wojciech Leppert ◽  
Marcin Janecki ◽  
Artur Pakosz ◽  
Mark Lomax ◽  
...  
Keyword(s):  
Cancer Pain ◽  
Prolonged Release ◽  
Safety And Efficacy ◽  
Chronic Cancer Pain

scholarly journals A comparative study of controlled-release morphine (CRM) suspension and CRM tablets in chronic cancer pain

1992 ◽  
Vol 7 (7) ◽  
pp. 393-399 ◽  
Author(s):  
François Boureau ◽  
François Saudubray ◽  
Christine d'Arnoux ◽  
Jacques Vedrenne ◽  
Marc Estève ◽  
...  
Keyword(s):  
Controlled Release ◽  
Comparative Study ◽  
Cancer Pain ◽  
Chronic Cancer Pain

A Pain Education Program for chronic cancer pain patients: follow-up results from a randomized controlled trial

Pain ◽  
1997 ◽  
Vol 73 (1) ◽  
pp. 55-69 ◽  
Author(s):  
Rianne de Wit ◽  
Frits van Dam ◽  
Linda Zandbelt ◽  
Anneke van Buuren ◽  
Karin van der Heijden ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Cancer Pain ◽  
Education Program ◽  
Controlled Trial ◽  
Pain Education ◽  
Randomized Controlled ◽  
Chronic Cancer Pain ◽  
Pain Patients

Use of opioids in patients with cancer with hepatic impairment—a systematic review

2021 ◽  
pp. bmjspcare-2021-003065
Author(s):  
Lewis Thomas Hughes ◽  
David Raftery ◽  
Paul Coulter ◽  
Barry Laird ◽  
Marie Fallon
Keyword(s):  
Systematic Review ◽  
Cancer Pain ◽  
Hepatic Impairment ◽  
Evaluation System ◽  
Meta Analysis ◽  
Hepatic Function ◽  
Cochrane Central Register ◽  
Assessment Development ◽  
Patients With Cancer ◽  
Central Register

PurposeOpioids are recommended for moderate-to-severe cancer pain; however, in patients with cancer, impaired hepatic function can affect opioid metabolism. The aim of this systematic review was to evaluate the evidence for the use of opioids in patients with cancer with hepatic impairment.MethodsA systematic review was conducted and the following databases searched: AMED (−2021), MEDLINE (−2021), EMBASECLASSIC + EMBASE (−2021) and Cochrane Central Register of Controlled Trials (−2021). Eligible studies met the following criteria: patients with cancer-related pain, taking an opioid (as defined by the WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents); >18 years of age; patients with hepatic impairment defined using recognised or study-defined definitions; clinical outcome hepatic impairment related; and primary studies. All eligible studies were appraised using the Grading of Recommendations Assessment, Development and Evaluation system.ResultsThree studies (n=95) were eligible but heterogeneity meant meta-analysis was not possible. Each individual study focused on only one each of oxycodone±hydrocotarnine, oxycodone/naloxone and morphine. No recommendations could be formulated on the preferred opioid in patients with hepatic impairment.ConclusionsMorphine is the preferred opioid in hepatic impairment owing to clinical experience and pharmacokinetics. This review, however, found little clinical evidence to support this. Dose adjustments of morphine and the oxycodone formulations reviewed remain necessary in the absence of quality evidence. Overall, the quality of existing evidence on opioid treatments in cancer pain and hepatic impairment is low and there remains a need for high-quality clinical studies examining this.

scholarly journals Correction to: The impact of social-emotional context in chronic cancer pain: patient-caregiver reverberations

2018 ◽  
Vol 27 (2) ◽  
pp. 715-715
Author(s):  
Martina De Laurentis ◽  
Rossana Botto ◽  
Andrea Bovero ◽  
Riccardo Torta ◽  
Valentina Ieraci
Keyword(s):  
Cancer Pain ◽  
Pain Patient ◽  
Social Emotional ◽  
Emotional Context ◽  
Chronic Cancer Pain ◽  
The Impact

scholarly journals Treatment of chronic cancer pain in urologic patients

2019 ◽  
Vol 41 (5-6) ◽  
pp. 97-106
Author(s):  
Nebojša Lađević ◽  
Vesna Jovanović ◽  
Jelena Jovičić ◽  
Nikola Lađević
Keyword(s):  
Cancer Pain ◽  
Chronic Cancer Pain
Sign in / Sign up

Export Citation Format

Share Document